Frontier in Japan – Dr Martin Burow & Dr Chris Lee

FRONTIER EXPANDS CLINICAL NETWORK AND SHOWCASES qCTC PLATFORM IN JAPAN

Frontier’s Dr. Martin Burow and Dr. Chris Lee have just returned from Japan, where they expanded the company’s clinical network and accelerated discussions on the use of Frontier’s Circulating Tumour Cell (qCTC) platform within one of the world’s most advanced oncology health systems.

“The trip completely exceeded my expectations. I had not expected to have the opportunity to meet so many key opinion leaders in oncology face-to-face and to see their immediate enthusiasm and real interest in working with us,” said Dr. Lee.

Frontier’s qCTC technology was exceptionally well received, with Japan’s leading researchers and biotech innovators recognising its potential to transform cancer monitoring. The vision of real-time, personalised treatment resonated strongly, particularly given that many current approaches still rely on outdated or static monitoring techniques. qCTC was viewed as a breakthrough tool that could help redefine standards of care.

Looking ahead, Dr. Burow commented: “Several major centres want to integrate qCTC into both NIH-funded and domestic clinical trials, so we are very excited to begin this next phase of work in Japan. The whole trip could not have gone better.”

Our own Dr Chris Lee was recently awarded a Fellowship of the Faculty of Pharmaceutical Physicians

Receiving the Fellowship of the Faculty of Pharmaceutical Physicians represented a significant milestone in my professional journey. On the day of the award, I was honoured to receive it from the President of the Faculty, an occasion that reflected not only personal achievement but also the recognition of sustained contributions to the field of pharmaceutical medicine. The fellowship is a formal acknowledgement of commitment to advancing standards of practice, supporting innovation, and ensuring the safe and effective development of medicines. Among my professional achievements, I am most proud of contributing to initiatives that have improved clinical research standards and patient safety, while also mentoring colleagues and supporting the development of future leaders in the discipline. The award serves as both recognition of past accomplishments and motivation to continue advancing the profession.